Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Game Over: FDA Warns Aventis For Repeat Use Of Taxotere Chess-Theme Ads

Executive Summary

Aventis' chess-themed direct-to-consumer ads for the breast and lung cancer therapy Taxotere "misleadingly...imply that survival depends on treatment with Taxotere," FDA told the company in a warning letter

You may also be interested in...



Rep. Waxman Challenges FDA Contact With Rx Companies On DTC Guides

Rep. Henry Waxman (D-Calif.) is asking FDA to defend its communications with pharmaceutical companies relating to the development of direct-to-consumer advertising guidances

Rep. Waxman Challenges FDA Contact With Rx Companies On DTC Guides

Rep. Henry Waxman (D-Calif.) is asking FDA to defend its communications with pharmaceutical companies relating to the development of direct-to-consumer advertising guidances

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

Latest News
See All
UsernamePublicRestriction

Register

PS042984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel